Literature DB >> 23552383

p16 is superior to ProEx C in identifying high-grade squamous intraepithelial lesions (HSIL) of the anal canal.

Rajeev Bala1, Benjamin A Pinsky, Andrew H Beck, Christina S Kong, Mark L Welton, Teri A Longacre.   

Abstract

Although the incidence of human papillomavirus (HPV)-associated anal neoplasia is increasing, interobserver and intraobserver reproducibility in the grading of biopsy specimens from this area remains unacceptably low. Attempts to produce a more reproducible grading scheme have led to the use of biomarkers for the detection of high-risk HPV (HR-HPV). We evaluated the performance of standard morphology and biomarkers p16, ProEx C, and Ki-67 in a set of 75 lesions [17 nondysplastic lesions, 23 low-grade squamous intraepithelial lesions (LSIL)/condyloma, 20 high-grade squamous intraepithelial lesions (HSIL), 15 invasive squamous cell carcinomas] from the anal and perianal region in 65 patients and correlated these findings with HPV subtype on the basis of a type-specific multiplex real-time polymerase chain reaction assay designed to detect HR-HPV. A subset of cases with amplifiable HPV DNA was also sequenced. HSIL was typically flat (15/20), and only a minority (4/20) had koilocytes. In contrast, only 1 LSIL was flat (1/23), and the remainder were exophytic. The majority of LSIL had areas of koilocytic change (20/23). HR-HPV DNA was detected in the majority (89%) of invasive carcinomas and HSIL biopsies, 86% and 97% of which were accurately labeled by strong and diffuse block-positive p16 and ProEx C, respectively. LSIL cases, however, only infrequently harbored HR-HPV (13%); most harbored low-risk HPV (LR-HPV) types 6 and 11. Within the LSIL group, p16 outperformed ProEx C, resulting in fewer false-positive cases (5% vs. 75%). Ki-67 was also increased in HR-HPV-positive lesions, although biopsies with increased inflammation and reactive changes also showed higher Ki-67 indices. These data suggest that strong and diffuse block-positive nuclear and cytoplasmic labeling with p16 is a highly specific biomarker for the presence of HR-HPV in anal biopsies and that this finding correlates with high-grade lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552383      PMCID: PMC4847144          DOI: 10.1097/PAS.0b013e31828706c0

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  45 in total

Review 1.  MCM proteins in DNA replication.

Authors:  B K Tye
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology.

Authors:  Maria Donatella Beccati; Carolina Buriani; Massimo Pedriali; Sonia Rossi; Italo Nenci
Journal:  Cancer       Date:  2008-06-25       Impact factor: 6.860

3.  Do HPV-negative cervical carcinomas exist?--revisited.

Authors:  C S Herrington
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.

Authors:  Ann E Walts; Juan Lechago; Shikha Bose
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

Review 5.  Anal cancer in renal transplant patients.

Authors:  Heena S Patel; Andrew R J Silver; John M A Northover
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

6.  Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus.

Authors:  Peter V Chin-Hong; Joel M Palefsky
Journal:  Clin Infect Dis       Date:  2002-10-14       Impact factor: 9.079

7.  Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients.

Authors:  O A Ogunbiyi; J H Scholefield; A T Raftery; J H Smith; S Duffy; F Sharp; K Rogers
Journal:  Br J Surg       Date:  1994-03       Impact factor: 6.939

8.  BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix.

Authors:  Riem E Badr; Ann E Walts; Fai Chung; Shikha Bose
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

9.  Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia.

Authors:  Sarah M Bean; Isam Eltoum; Debra K Horton; Leisa Whitlow; David C Chhieng
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

10.  Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.

Authors:  Anette Thyssen Jonstrup; Tina Thomsen; Yong Wang; Birgitta R Knudsen; Jørn Koch; Anni H Andersen
Journal:  Nucleic Acids Res       Date:  2008-09-29       Impact factor: 16.971

View more
  4 in total

Review 1.  Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia.

Authors:  Kevin C Long; Raman Menon; Amir Bastawrous; Richard Billingham
Journal:  Clin Colon Rectal Surg       Date:  2016-03

Review 2.  Pigmented anal squamous intraepithelial neoplasia: a case report and review of literature.

Authors:  Mitsuaki Ishida; Muneo Iwai; Akiko Kagotani
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

3.  Characterization of topoisomerase II α and minichromosome maintenance protein 2 expression in anal carcinoma.

Authors:  Cristovam Scapulatempo-Neto; Carlos Veo; José Humberto T G Fregnani; Adriana Lorenzi; Allini Mafra; Armando G F Melani; Edgar Antonio Alemán Loaiza; Luciana Albina Reis Rosa; Cristina Mendes de Oliveira; José Eduardo Levi; Adhemar Longatto-Filho
Journal:  Oncol Lett       Date:  2017-01-25       Impact factor: 2.967

4.  Squamous intraepithelial lesions of the anal squamocolumnar junction: Histopathological classification and HPV genotyping.

Authors:  Omar Clavero; Jenny McCloskey; Vicente Marco Molina; Beatriz Quirós; Ignacio G Bravo; Silvia de Sanjosé; F Xavier Bosch; Ville N Pimenoff
Journal:  Papillomavirus Res       Date:  2016-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.